alzheimer disease Clinical Trials and Research
Also known as: ad, senile dementia of the alzheimer type, dementia, alzheimer's type, alzheimer's, late-onset alzheimer's, early-onset alzheimer's, familial alzheimer's disease · ICD-10: G30
Alzheimer's disease is a progressive brain disorder that gradually destroys memory and thinking skills. Clinical trial research is actively exploring new ways to prevent, treat, and even cure this condition, focusing on various biological targets. Find a Trial helps patients and caregivers search for active studies.
Search alzheimer disease trials →
Common questions about alzheimer disease clinical trials
Who can participate in Alzheimer's clinical trials?
Eligibility criteria vary greatly by study, often depending on age, disease stage, and overall health. Some trials seek participants with early memory changes, while others focus on more advanced stages. This information is detailed on ClinicalTrials.gov, helping patients understand specific requirements.
What are the different phases of Alzheimer's clinical trials?
Clinical trials for Alzheimer's disease progress through phases 1, 2, and 3. Phase 1 studies test safety, Phase 2 evaluates effectiveness and side effects, and Phase 3 confirms efficacy and monitors adverse reactions in larger groups. Data is publicly available on ClinicalTrials.gov.
Do clinical trials for Alzheimer's disease cost money to participate in?
Generally, participation in clinical trials does not involve direct costs to the patient for study-related care, tests, or investigational treatments. However, travel or other personal expenses are typically not covered. Specifics are outlined in the informed consent process for each study.
What are current research directions in Alzheimer's disease clinical trials?
Current research focuses on targeting amyloid plaques and tau tangles, reducing neuroinflammation, and exploring genetic factors. Scientists are also investigating lifestyle interventions and new diagnostic tools. This broad research landscape is visible on ClinicalTrials.gov and NIH RePORTER.
What types of interventions are being studied in Alzheimer's trials?
Interventions include various investigational drugs, such as monoclonal antibodies targeting amyloid or tau, and small molecules aimed at different disease pathways. Non-pharmacological approaches, like cognitive training or dietary changes, are also being explored. Details are on ClinicalTrials.gov.
What biomarkers are important in Alzheimer's disease clinical trials?
Key biomarkers include amyloid-beta and tau levels in cerebrospinal fluid or via PET scans, and brain volume changes seen on MRI. These help identify disease presence, monitor progression, and assess treatment effects. Researchers use these extensively, as seen on ClinicalTrials.gov.
What are common reasons someone might not be eligible for an Alzheimer's trial?
Common exclusion criteria can include other neurological conditions, significant medical comorbidities, certain medications, or a history of specific psychiatric disorders. These ensure participant safety and study integrity. Each trial's detailed criteria are listed on ClinicalTrials.gov.
Are there clinical trials focused on early detection or prevention of Alzheimer's?
Yes, many trials are dedicated to identifying Alzheimer's disease at its earliest stages, even before significant symptoms appear. Others investigate interventions for individuals at high risk to potentially delay or prevent onset. Information is available on ClinicalTrials.gov and NIH RePORTER.
How to find a alzheimer disease trial that fits you
- Describe your alzheimer disease situation in detail — stage if applicable, prior treatments, age, and other relevant conditions.
- Use the location filter (worldwide, US, US & Canada, Europe) to narrow to trials near you.
- Review each trial's eligibility criteria carefully. Save 2–5 candidates with their NCT numbers.
- Discuss with your treating clinician before contacting the research site.
Browse all alzheimer disease trials →